“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

2024.02.21
Breast cancer is the most common malignancy among women globally, with an increasing incidence rate that poses a significant threat to women's health worldwide. Molecular typing aids in the precise classification and stratified treatment of breast cancer. The continuous development of immunotherapy and targeted therapy offers new treatment options for patients with different types. At the recent 2023 China Conference of Integrated Oncology (CCHIO 2023), "Tumor Watch" had the opportunity to interview Professor Zhang Jin from Tianjin Medical University Cancer Hospital at the venue. Professor Zhang discussed the current state of breast cancer research in China, reviewed the evolution of breast cancer treatment strategies, and shared insights into the precision treatment of patients with different types.
ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

ESMO Hot Topics Update: New Developments in Precision Diagnosis and Treatment with Talazoparib

2024.02.20
At this year's recently concluded ESMO conference, new developments related to the PARP inhibitor talazoparib in precision diagnosis and treatment were announced. Precision diagnosis has become a leading trend in the field of prostate cancer, and biomarker research is receiving increasing attention. In this context, this publication invited Professor Zhang Guiming from Qingdao University Affiliated Hospital, a well-known young expert in the field of prostate cancer, for an in-depth interview to explain the three new developments related to talazoparib's precision treatment recently announced at ESMO. Here, we provide a summary of the interview for the readers.

Understanding and Managing Chronic Hepatitis B: The Importance of Detailed Assessment

2024.02.20
Since the introduction of the first oral nucleos(t)ide analogs (NAs) lamivudine for the treatment of chronic hepatitis B (CHB)  in China in 1998, there has been a continuous effort over 25 years to explore various generations of drugs by medical, pharmaceutical, and technological researchers. The NA family has expanded to include entecavir, telbivudine, tenofovir disoproxil fumarate, tenofovir alafenamide, besifovir and so on. In particular, the latter four have become the mainstay for controlling hepatitis B virus (HBV). Additionally, long-acting interferons, when used in combination or sequentially with NAs, enhance the treatment's effectiveness, providing hope for reaching new heights in the cure of HBV.
CASH interview | Professor Jinghui Zhang: Monitoring clonal hematopoiesis in pediatric patients to help improve long-term prognosis

CASH interview | Professor Jinghui Zhang: Monitoring clonal hematopoiesis in pediatric patients to help improve long-term prognosis

2024.02.20
Clonal hematopoiesis usually refers to myeloid cell proliferation caused by genetic mutations in hematopoietic stem cells, and is also the basis of the pathogenesis of various blood diseases; monitoring clonal hematopoiesis can enable early detection of hematological malignancies. At the 4th CASH held recently, Professor Jinghui Zhang from St. Jude Children's Research Hospital shared the report "Treatment-Related Clonal Hematopoiesis in Adult Survivors of Childhood Cancer". After the meeting, " Oncology Frontier-Hematology Frontier" specially invited Professor Jinghui Zhang to give an in-depth sharing on the treatment-related causes, monitoring value and long-term impact of clonal hematopoiesis.